Neurotrope – Company in a Quandary over Failure of Alzheimer’s Clinical Trial
Neurotrope Inc, (NASDAQ: NTRP) announced a setback, with Bryostatin, its lead candidate for the treatment of Alzheimer’s, failing to meet its clinical endpoints of its mid-stage study. The Topline results from the confirmatory Phase 2 study of Bryostatin-1, in moderate to severe Alzheimer’s, failed to achieve...
